论文部分内容阅读
目的 评价骨细胞同种异体移植物(CBA)在踝关节融合术中的有效性与安全性.方法 踝关节外伤或术后踝关节创伤性关节炎患者56例,采用踝关节融合术治疗,根据术中是否采用CBA填塞分为两组,CBA组33例,术中采用CBA填塞;非CBA组23例,术中未采用CBA填塞.术后2个月对患者进行影像学检查,并记录患者的视觉模拟(VAS)评分、美国足踝外科协会(AOFAS)踝-后足评分和SF-36健康状况问卷评分.结果 术后2个月,未使用CBA组融合率为52.2 %,使用CBA组融合率为87.9%;术后3个月,未使用CBA组融合率为77.3%,使用CBA组融合率96.9%.高危患者(如糖尿病或肥胖)的融合率与正常患者融合率相当.使用CBA组患者疼痛、功能和生活质量有明显改善,无CBA相关的不良反应.结论 使用CBA治疗的患者,早期融合率及最终融合率均高于使用自体骨移植患者,并且不受高危因素的影响.CBA能促进踝关节融合,是一种安全、有效的移植材料.“,”Objective To evaluate the efficacy and safety of cellular bone allograft(CBA)in ankle arthrodesis.Methods The clinical data of 56 patients with traumatic ankle joint injury and ankle joint injury treated in our hospital from April 2013 to April 2016 were retrospectively analyzed.Imaging was performed at 3 months after surgery,and the visual analogue(VAS)score of the patients,the ankle and foot surgery score(AOFAS),and the SF-36 health status questionnaire score were recorded.The group included 33 patients who were treated with CBA,and patients with simple fusion in the treatment group(n=23).Results 2 months after operation,the fusion rate of CBA group was 87.9% and the fusion rate of without CBA group was 52.2%.3 months after operation,the fusion rate of CBA group was not higher than that of group CBA,and the fusion rate was in group.The data showed a significant improvement in pain,function,and quality of life.No adverse events caused by CBA were observed during the study.Conclusion The rate of fusion was higher in patients treated with bone allograft(CBA)than in patients with autologous bone graft,and the fusion rate was not affected by high risk factors.CBA is a safe and effective graft material for the bone healing of damaged joints,which can provide an effective bone graft substitute for ankle arthrodesis.